Leap Therapeutics, Inc. (NASDAQ:LPTX) to Post FY2022 Earnings of ($0.44) Per Share, HC Wainwright Forecasts

Leap Therapeutics, Inc. (NASDAQ:LPTXGet Rating) – HC Wainwright decreased their FY2022 EPS estimates for shares of Leap Therapeutics in a report issued on Wednesday, November 16th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.44) per share for the year, down from their previous forecast of ($0.38). The consensus estimate for Leap Therapeutics’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Leap Therapeutics’ Q4 2022 earnings at ($0.06) EPS, Q1 2023 earnings at ($0.11) EPS, Q2 2023 earnings at ($0.12) EPS, Q3 2023 earnings at ($0.12) EPS and FY2023 earnings at ($0.45) EPS.

Separately, Raymond James lowered their price target on shares of Leap Therapeutics from $3.50 to $2.50 and set an “outperform” rating on the stock in a report on Friday, November 11th.

Leap Therapeutics Stock Performance

Shares of NASDAQ LPTX opened at $0.61 on Friday. The company’s fifty day moving average price is $0.87 and its 200 day moving average price is $1.09. Leap Therapeutics has a 1 year low of $0.55 and a 1 year high of $3.45. The company has a market capitalization of $60.00 million, a PE ratio of -1.29 and a beta of 0.61.

Institutional Investors Weigh In On Leap Therapeutics

Hedge funds have recently modified their holdings of the business. Virtu Financial LLC raised its holdings in Leap Therapeutics by 44.2% in the second quarter. Virtu Financial LLC now owns 28,865 shares of the company’s stock valued at $33,000 after acquiring an additional 8,852 shares in the last quarter. Gilman Hill Asset Management LLC raised its holdings in Leap Therapeutics by 80.0% in the second quarter. Gilman Hill Asset Management LLC now owns 22,500 shares of the company’s stock valued at $26,000 after acquiring an additional 10,000 shares in the last quarter. Private Advisor Group LLC raised its holdings in Leap Therapeutics by 104.5% in the first quarter. Private Advisor Group LLC now owns 22,500 shares of the company’s stock valued at $39,000 after acquiring an additional 11,500 shares in the last quarter. BlackRock Inc. raised its holdings in Leap Therapeutics by 1.2% in the first quarter. BlackRock Inc. now owns 1,198,188 shares of the company’s stock valued at $2,098,000 after acquiring an additional 14,079 shares in the last quarter. Finally, Integrated Wealth Concepts LLC acquired a new stake in Leap Therapeutics in the first quarter valued at approximately $26,000. 38.08% of the stock is currently owned by institutional investors and hedge funds.

About Leap Therapeutics

(Get Rating)

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers.

Featured Articles

Earnings History and Estimates for Leap Therapeutics (NASDAQ:LPTX)

Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.